Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab

Sharma, Vivek R.; Fleming, Donald R.; Slone, Stephen P.

doi:10.1182/blood.v96.3.1184

Cited by 115 publications

(32 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it may result in fatal viral infections, such as HBV reactivation, parvovirus B19 and varicella-zoster infections (Bermudez et al, 2000;Sharma, Fleming & Slone, 2000;Hamaki et al, 2001;McIlwaine, Fitzsimons & Soutar, 2001;Ng & Lim, 2001;Skrabs et al, 2002;Song et al, 2002;Dai et al, 2004;Heider et al, 2004;Isobe et al, 2004;Tsutsumi et al, 2004). Data on HCV reactivation following rituximab are limited.…”

Section: Discussionmentioning

confidence: 99%

Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

et al. 2006

View full text Add to dashboard Cite

The treatment of patients with non-Hodgkin's lymphoma (NHL) may be complicated by concomitant chronic hepatitis C virus (HCV) infection. Recent data suggest that HCV may also be a contributing factor to the development of this disease. Although antiviral treatment has occasionally been reported to result in the regression of lymphoma in patients with HCV infection, the importance of the control of this infection on the prognosis of lymphoma needs to be defined. Here we report a patient with diffuse large B-cell lymphoma who presented with a mass in her left breast. She had had HCV-related liver cirrhosis for 6 years. She was given rituximab monotherapy for three consecutive weeks, but treatment had to be discontinued as a result of hematological toxicity. HCV viral load also increased, but then decreased gradually after rituximab was stopped. She could be given no further therapy. Six months later she presented with spinal involvement with infiltration of the cauda equina. Though cranial-spinal radiotherapy and steroids were started, she died shortly thereafter. Though rituximab is an invaluable drug in the treatment of B-cell lymphomas, we believe that the use of such agents with potentially long-lasting effects on B lymphocytes requires extended vigilance for accelerated replication of hepatitis B and C viruses.

show abstract

Section: Discussionmentioning

confidence: 99%

Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Parvovirus B19 antibodies present in IVIG are useful in the treatment of aplastic anemia, pure RBC aplasia, and vasculitis in infected patients. [144][145][146][147][148][149][150] However, the virus itself is detectable in IVIG using PCR and could theoretically pose an infectious threat to recipients. 151 A case of parvovirus B19 infection transmitted by heat-treated IVIG preparation that led to pure RBC aplasia has recently been reported, 152 as well as a possible superinfection with a new strain of parvovirus B19 in an already B19-infected IVIG recipient, based on a change in B19 DNA sequence after infusion.…”

Section: Infectious Disease Transmission and Screeningmentioning

confidence: 99%

Intravenous immune globulins: an update for clinicians

2003

View full text Add to dashboard Cite

“…A severe rituximab-induced Ôcytokine [interleukin (IL)-6 and tumour necrosis factor (TNF)a] release syndromeÕ, characterized by fever, chills, bronchospasm, hypotension, and thrombocytopenia, has been reported in patients with a very high B-cell tumour burden [16,25] but not in patients without neoplastic disease. Pure red cell aplasia caused by parvovirus B19, [26] and reactivation of acute hepatitis B [27] has been reported with rituximab. There have not, as yet, been long-term animal or human studies performed to establish the carcinogenic or mutagenic potential of rituximab or to determine its effects, if any, on fertility.…”

Section: Introductionmentioning

confidence: 99%

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

Carção

Louis

et al. 2005

Haemophilia

View full text Add to dashboard Cite

Summary. When a high titre inhibitor develops in a patient with haemophilia, attempts are made to eradicate it through immune tolerance induction therapy (ITI) involving the frequent and regular administration of factor, usually for months to years. ITI is successful in only two thirds of patients prompting investigators to explore alternate regimens to use in haemophiliacs failing conventional ITI. Rituximab is an anti-CD20 monoclonal antibody, which has shown promise in the treatment of B-cell-mediated disorders. We developed a protocol for the use of rituximab in haemophilia A (HA) patients failing conventional ITI or in those haemophiliacs where the likelihood of success of conventional ITI is poor. Patients receive 375 mg m )2 of intravenous rituximab weekly for 4 weeks followed by monthly (up to 5 months) until inhibitor disappearance and establishment of normal FVIII pharmacokinetics (recovery and half-life). Patients are concurrently placed on recombinant FVIII (100 U kg )1 day )1 ). We have placed five haemophiliacs (four children with severe HA, and one adult with mild HA) on this protocol. In three patients (two with severe HA and one with mild HA) inhibitors disappeared although in neither severe haemophiliac did FVIII pharmacokinetics completely normalize. The fourth patient had a significant drop in inhibitor titres although not a complete disappearance of the inhibitor. All four of these patients ceased bleeding following rituximab. The fifth patient had no response to rituximab. This nonresponding patient was not placed on concurrent FVIII. Our five cases suggest that rituximab may hold promise in the eradication of inhibitors. Prospective randomized studies are required to determine the value of this agent in inhibitor management.

show abstract

Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab

Cited by 115 publications

References 11 publications

Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

Intravenous immune globulins: an update for clinicians

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

Contact Info

Product

Resources

About